Alira Health Advises Aesculapius Farmaceutici Srl in Its Acquisition by Ceres Pharma NV

The transaction is expected to further expand Ceres Pharma’s presence in Italy and the business combination will create value for the pharmaceutical ecosystem via enhanced distributions and commercialization capabilities of the combined entity.  

“We were honored to serve as a transaction advisor representing the seller in this landmark deal,” said Carlo Stimamiglio, Partner, Transaction Advisory Services at Alira Health. “The acquisition will strengthen Ceres Pharma’s growth in Italy, creating value for the pharmaceutical ecosystem, and patients will benefit from the improved capabilities of the combined entity, ensuring enhanced accessibility and availability of pharmaceutical solutions in Europe and in Italy in particular.” 

“The acquisition of Aesculapius is a game changer for Ceres Pharma,” Mario Debel, CEO of Ceres Pharma, commented. “With Aesculapius and Amnol, which we recently acquired, we reach the required scale and structure to build a significant position in Italy. Thanks to Aesculapius’ strong product portfolio, international drug registrations and international network of distributors, we will also be able to accelerate the growth of our CEE and export businesses.” 

“We are confident to hand over our family business to a strong, dynamic and fast growing international group, such as Ceres Pharma,” Dr. Enzo Moroni, former main shareholder and GM of Aesculapius, said. “Together, we will be stronger to execute our ambitious growth plan in Italy and beyond.” 

For more information on the acquisition, read the press release at Ceres Pharma. To learn more about Alira Health’s transaction advisory services, and other consulting and clinical services enabled by technology and real-world evidence, visit AliraHealth.com.